home / stock / elox / elox quote
Last: | $3.82 |
---|---|
Change Percent: | 0.0% |
Open: | $4.05 |
Close: | $3.82 |
High: | $4.29 |
Low: | $3.79 |
Volume: | 45,132 |
Last Trade Date Time: | 10/13/2023 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$3.82 | $4.05 | $3.82 | $4.29 | $3.79 | 45,132 | 10-13-2023 |
$4.05 | $4.23 | $4.05 | $4.245 | $3.91 | 28,162 | 10-12-2023 |
$4.15 | $4.4 | $4.15 | $4.4 | $4.1 | 12,523 | 10-11-2023 |
$4.36 | $4.39 | $4.36 | $4.49 | $4.15 | 10,046 | 10-10-2023 |
$4.4 | $4.3 | $4.4 | $4.48 | $4.2119 | 18,097 | 10-09-2023 |
$4.32 | $4.46 | $4.32 | $4.53 | $4.2 | 25,935 | 10-06-2023 |
$4.51 | $4.74 | $4.51 | $4.74 | $4.51 | 5,037 | 10-05-2023 |
$4.58 | $4.66 | $4.58 | $5.09 | $4.5301 | 39,988 | 10-04-2023 |
$4.78 | $4.51 | $4.78 | $5.18 | $4.51 | 32,489 | 10-03-2023 |
$4.76 | $4.68 | $4.76 | $4.8 | $4.6 | 3,938 | 10-02-2023 |
$4.81 | $4.78 | $4.81 | $5 | $4.69 | 16,515 | 09-29-2023 |
$4.63 | $4.99 | $4.63 | $5.0194 | $4.63 | 14,949 | 09-28-2023 |
$4.92 | $4.97 | $4.92 | $5.1789 | $4.8992 | 8,909 | 09-27-2023 |
$4.94 | $4.78 | $4.94 | $5.2 | $4.78 | 24,198 | 09-26-2023 |
$4.84 | $4.98 | $4.84 | $5.4616 | $4.71 | 16,300 | 09-25-2023 |
$5.02 | $4.86 | $5.02 | $5.245 | $4.86 | 11,500 | 09-22-2023 |
$4.86 | $5.42 | $4.86 | $5.4899 | $4.66 | 42,914 | 09-21-2023 |
$5.53 | $5.4 | $5.53 | $5.62 | $5.3 | 10,406 | 09-20-2023 |
$5.55 | $5.45 | $5.55 | $5.55 | $5.2732 | 20,836 | 09-19-2023 |
$5.46 | $5.99 | $5.46 | $5.99 | $5.26 | 56,342 | 09-18-2023 |
News, Short Squeeze, Breakout and More Instantly...
Eloxx Pharmaceuticals Inc. Company Name:
ELOX Stock Symbol:
NASDAQ Market:
Eloxx Pharmaceuticals Inc. Website:
ELX-02 Granted Orphan Drug Designation (ODD) from U.S. Food and Drug Administration (FDA) for Treatment of Alport Syndrome Pre-Investigational New Drug (IND) Meeting Requested with U.S. FDA for ELX-02 to Discuss Planned next Study In Nonsense Mutation Alport Syndrome Signed Glob...
GD Culture Group Limited (GDC) is expected to report for Q4 2023 Citizens Inc. Class A ($1.00 Par) (CIA) is expected to report for quarter end 2023-12-31 Escalade Incorporated (ESCA) is expected to report for Q4 2023 Lendway Inc. (LDWY) is expected to report for quarter end 2023-12-31...
Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the treatment of rare dermatological and other diseases associated with nonsense mutations ZKN-013 is a phase I ready oral therapy designed to overcome nonsense mutations that cause a premature stop codon ...